Related Experiment Video
Updated: Jul 5, 2026
05:54
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
Published on: September 5, 2018
Activated Raf-1 causes growth arrest in human small cell lung cancer cells
1The Oncology Center, The Johns Hopkins University Medical Institutions, Baltimore, Maryland 21287, USA.
The Journal of Clinical Investigation
|February 14, 1998
Summary
Activating the raf/MEK/mitogen-activated protein kinase (MAPK) pathway in small cell lung cancer (SCLC) cells suppressed growth and induced cell cycle arrest. This suggests targeting MAPK pathway activation could be a novel therapeutic strategy for SCLC.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor prognosis.
- Unlike other lung cancers, SCLC lacks ras mutations, suggesting unique signaling pathway involvement.
- The raf-MEK-MAPK pathway is a key signaling cascade implicated in cancer cell proliferation.
Purpose of the Study:
- To investigate the biological effects of activating the raf-MEK-MAPK pathway in SCLC cells.
- To determine if MAPK pathway activation influences SCLC cell growth, cell cycle, and key regulatory proteins.
- To explore the therapeutic potential of targeting MAPK pathway activation in SCLC.
Main Methods:
- Transfection of SCLC cell lines (NCI-H209, NCI-H510) with a fusion gene (DeltaRaf-1:ER) to enable inducible Raf-1 activation.
- Assessment of MAPK phosphorylation levels following DeltaRaf-1:ER activation.
- Evaluation of cellular proliferation, soft agar cloning ability, and cell cycle distribution.
- Analysis of cyclin-dependent kinase (cdk) inhibitor p27(kip1) expression and cdk2 kinase activity.
- Inhibition studies using the MEK inhibitor PD098059.
Main Results:
- Activation of DeltaRaf-1:ER led to robust MAPK phosphorylation in SCLC cells.
- MAPK pathway activation significantly suppressed growth capacity and soft agar cloning ability.
- Cell cycle analysis revealed cell accumulation in G1 and G2 phases with S phase depletion.
- Raf activation induced a marked increase in p27(kip1) levels and decreased cdk2 kinase activity.
- The observed effects were reversible by pretreatment with the MEK inhibitor PD098059.
Conclusions:
- MAPK pathway activation by DeltaRaf-1:ER induces potent growth inhibitory signals and cell cycle arrest in SCLC.
- The raf/MEK/MAPK pathway, when activated, leads to cell cycle arrest through mechanisms involving p27(kip1) and cdk2.
- Targeting MAPK pathway activation, rather than inhibition, may represent a novel therapeutic strategy for SCLC and other neuroendocrine tumors.
More Related Videos
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
06:44Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
Published on: March 1, 2024
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...